Studienpraxis Urologie Susan Feyerabend MD Tilman Todenhoefer MD PhD GbR

At Studienpraxis Urologie Susan Feyerabend MD Tilman Todenhoefer MD PhD GbR in Nuertingen, a major focus is on neoplasms affecting the urinary tract, especially bladder cancer and urothelial carcinoma. These studies are designed to test new treatment options, improve disease control, and compare emerging approaches with current standard care.

• High-risk non-muscle-invasive bladder cancer and non-muscle-invasive urothelial carcinoma
• Locally advanced or metastatic urothelial carcinoma
• Bladder cancer with FGFR alterations or BCG-unresponsive disease

The research includes efforts to strengthen local bladder-sparing treatment, evaluate immune-based combinations, and explore ways to better prevent recurrence and progression.

A second prominent area at this German site is prostate cancer research, covering both advanced and earlier metastatic disease. The trials focus on improving outcomes for men with metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer, with particular attention to treatment effectiveness and disease progression.

• Metastatic castration-resistant prostate cancer
• Metastatic castration-sensitive prostate cancer
• Metastatic hormone-sensitive prostate cancer with PTEN deficiency or HRR gene mutations

Many of these studies aim to determine whether newer targeted or combination therapies can delay progression and extend the time patients live without their cancer worsening.

The site also contributes to broader oncology research beyond one cancer type, including studies in colorectal cancer, hepatocellular cancer, non-small cell lung cancer, and head and neck squamous cell carcinoma. These trials are mainly evaluating new therapy combinations and assessing how well they work in advanced solid tumors.

• Advanced solid tumors
• Colorectal cancer, hepatocellular cancer, and non-small cell lung cancer
• Head and neck squamous cell carcinoma

This line of research reflects a strong interest in targeted therapy and immunotherapy, with the goal of finding more effective options for difficult-to-treat cancers.

Several trials at the site explore new ways to treat non-muscle-invasive bladder cancer using BCG-based strategies, immune treatments, and intravesical approaches. These studies are designed to improve disease-free survival, increase complete response rates, and offer alternatives for patients who do not respond well to standard therapy.

• BCG-naïve high-risk bladder cancer
• BCG-unresponsive disease
• Intravesical and immune-based bladder cancer treatment

This research highlights a strong commitment to refining local treatment for bladder tumors while reducing the chance of recurrence.

The trial portfolio at Studienpraxis Urologie Susan Feyerabend MD Tilman Todenhoefer MD PhD GbR includes a clear emphasis on precision medicine, especially for patients whose cancers carry specific molecular features such as HRR, BRCA, PTEN, or FGFR alterations. These studies aim to match treatment more closely to tumor biology and improve outcomes through personalized therapy.

• Genomically defined prostate cancer
• FGFR-altered bladder cancer
• BRCA-mutated and HRR-mutated advanced cancers

The overall goal is to evaluate whether biomarker-driven treatment choices can better control advanced disease than standard approaches.